Biogen Stock Plunges as Tau-Targeting Alzheimer's Therapy Misses Trial Endpoints
Biogen shares fell after a clinical trial for an Alzheimer's disease therapy targeting tau protein failed to meet primary endpoints. The disappointing data undermines confidence in the company's pipeline beyond its amyloid franchise and heightens uncertainty about future revenue growth in neuroscience.
- ▼ Alzheimer's tau trial failure published on July 14, 2026
- ▼ Biogen's tau therapy fails to meet primary endpoints
- ▲ Positive data from other Alzheimer's programs could offset the impact
- ▲ If the sell-off is viewed as overdone, value buyers might step in
▼ Show FAQ (3) ▲ Hide FAQ
Why did Biogen shares drop?
Biogen shares declined after the company reported that its investigational anti-tau Alzheimer's therapy did not meet its primary endpoints in a key clinical trial, disappointing investors who hoped the tau approach would succeed where amyloid therapies have had mixed results.
What is the long-term impact for Biogen?
The failure of the tau trial reduces the probability of Biogen bringing a new Alzheimer's drug to market, potentially limiting long-term growth. It may force the company to rely more on its existing multiple sclerosis franchise and other pipeline assets, which could affect valuation multiples.
Should investors sell Biogen stock?
The article does not provide investment advice, but the disappointing trial data may lead analysts to revise their ratings and price targets downward. Investors should assess their risk tolerance given the increased uncertainty.